- Home
- MNSB vs AVTX Comparison
MNSB vs AVTX Comparison
Compare MNSB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- AVTX
- Stock Information
- Founded
- MNSB 2003
- AVTX 2011
- Country
- MNSB United States
- AVTX United States
- Employees
- MNSB N/A
- AVTX N/A
- Industry
- MNSB Major Banks
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MNSB Finance
- AVTX Health Care
- Exchange
- MNSB Nasdaq
- AVTX Nasdaq
- Market Cap
- MNSB 170.1M
- AVTX 138.8M
- IPO Year
- MNSB N/A
- AVTX 2015
- Fundamental
- Price
- MNSB $21.64
- AVTX $10.93
- Analyst Decision
- MNSB
- AVTX Strong Buy
- Analyst Count
- MNSB 0
- AVTX 8
- Target Price
- MNSB N/A
- AVTX $31.00
- AVG Volume (30 Days)
- MNSB 14.5K
- AVTX 209.8K
- Earning Date
- MNSB 10-27-2025
- AVTX 11-06-2025
- Dividend Yield
- MNSB 1.85%
- AVTX N/A
- EPS Growth
- MNSB N/A
- AVTX N/A
- EPS
- MNSB N/A
- AVTX N/A
- Revenue
- MNSB $64,604,000.00
- AVTX $441,000.00
- Revenue This Year
- MNSB $23.19
- AVTX N/A
- Revenue Next Year
- MNSB $2.92
- AVTX N/A
- P/E Ratio
- MNSB N/A
- AVTX N/A
- Revenue Growth
- MNSB N/A
- AVTX N/A
- 52 Week Low
- MNSB $15.00
- AVTX $3.39
- 52 Week High
- MNSB $22.98
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- MNSB 48.90
- AVTX 63.09
- Support Level
- MNSB $21.09
- AVTX $10.72
- Resistance Level
- MNSB $22.00
- AVTX $12.41
- Average True Range (ATR)
- MNSB 0.28
- AVTX 0.87
- MACD
- MNSB -0.17
- AVTX 0.01
- Stochastic Oscillator
- MNSB 29.10
- AVTX 59.04
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).